跳至主要内容
临床试验/NCT01250236
NCT01250236Unknown不适用

Effect of Brimonidine on Corneal Thickness

Augenarztpraxis Breisach1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2010年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
10
试验地点
1
主要终点
corneal thickness

研究概览

简要总结

Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors there are only few studies available on the impact brimonidine has on the cornea. The aim of the study is to find out

  1. whether topical administration of brimonidine results in interaction with corneal alpha-2 adrenoceptors in terms of an increase in corneal thickness and
  2. whether there are any differences between the response corneal epithelium, stroma and endothelium show to alpha-2 adrenoceptor stimulation.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • healthy, 18-99 years, normal ophthalmologic history, consent to participate in the study

排除标准

  • any serious medical or neurologic conditions and/or regular use of local or systemic medications

研究组 & 干预措施

verum

brimonidine 0.1% eye drops twice daily

干预措施: brimonidine 0.1% (Drug)

placebo

sodium hyaluronate 1.8mg/ml eye drops twice daily

干预措施: placebo (Drug)

结局指标

主要结局

corneal thickness

时间窗: 5 days

次要结局

  • intraocular pressure(5 days)

研究者

发起方
Augenarztpraxis Breisach
申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Effect of Brimonidine on Corneal Thickness | 临床试验